Dr. Reddy’s Laboratories has entered a strategic collaboration with international biotech firm Alvotech to co-develop and commercialize a biosimilar candidate targeting Keytruda (pembrolizumab), a leading immuno-oncology drug with global sales exceeding USD 29.5 billion in 2024. This partnership leverages the combined expertise of both companies in biosimilar innovation, aiming to expedite product development and broaden market access worldwide. The agreement entails joint responsibility for development, manufacturing, and cost-sharing, positioning Dr.